All phase III results published
June 22, 2010
MEDICINES Australia has
welcomed a new commitment from
the International Federation of
Pharmaceutical Manufacturers and
Associations to submit the results of
all phase III trials for scientific
journal publication, regardless of
whether the trial’s outcome was
positive or negative.
The new policy, cemented last
week, requires IFPMA members to
submit the results of all their
industry-sponsored Phase III trials,
to peer-reviewed scientific journals.
This new practice, according to
MA chief executive officer, Dr
Brendan Shaw, will lead to greater
transparency in clinical research.
“Transparency and openness are
critical in ensuring the pharmaceutical
industry maintains the trust of the
community,” said Shaw.
“Medicines Australia members
and other members of the IFPMA
already disclose the clinical trials
they are undertaking in online
registries. This new policy position
commits to a further level of
transparency,” he added.
The new policy also requires
members to disclose all company
involvement in both the trials
research and publication.
The IFPMA is also strongly urging
trial sponsors to “encourage”
authors to disclose all relevant
interests within their papers.
IFPMA members will have to
submit their results no later than 18
months after receiving approvals or
after having ceased trials.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Jun 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Jun 10
